With the highest professional and ethical standards, we commercialise therapies and technologies that uniquely fulfil the unmet medical needs of our community.

HCP Portal
Access Programs

ST has added three endocrinology therapies to its specialist portfolio. Our commitment is to make a difference for patients with hypoparathyroidism, growth hormone deficiency and achondroplasia.

ST therapies have been used to treat

~85,000

patients

ST has donated
more than

$34.2 million

worth of drugs to patients at no cost on compassionate grounds

ST has contributed
more than

$5.2 million

to research and development

ST has provided
more than

$2.4 million

in donations, grants and sponsorship to organisations aligned with its focus and mission

ST has established partnerships with

16

international companies, commercialising their therapies in key regions

Meeting the unmet needs

of patients in Australia,

New Zealand and
Southeast Asia

Our Partners

We collaborate with international partner companies , championing their speciality products from pre-registration through to full commercialisation

We are a member of World Orphan Drug Alliance (WODA), an international consortium of pharmaceutical companies established to improve access to new treatments for rare diseases

More Info

Access Programs

MORE INFO

Press Releases

All Company Announcements

Our Story

LEARN MORE

Latest News

February 15, 2024

Building from a Solid Foundation: The Future of MedTech in Australia

by Specialised Therapeutics | 0 Comments

ST has featured in the latest MedTech Sector report published by financial services and corporate advisory firm RSM. ...

November 2, 2023

Patient Experience – Small Cell Lung Cancer

by Comms Department | 0 Comments

57 year old Lay Har has never been a smoker and has always considered herself relatively healthy, was ...

October 13, 2023

Specialised Therapeutics Signs Exclusive License Agreement with CanariaBio for New Ovarian Cancer Therapy

by Comms Department | 0 Comments

First ovarian cancer therapy for ST oncology portfolio Phase 2 study demonstrated oregovomab in combination with chemotherapy improved ...

October 4, 2023

Breast Cancer Awareness Month: Meet the Specialist

by Comms Department | 0 Comments

Consultant Clinical Oncologist Dr Aqilah Othman says an ageing population, fewer and later pregnancies, a lack of physical ...

September 8, 2023

World Orphan Drug Alliance Welcomes Specialised Therapeutics

by Comms Department | 0 Comments

SEA’s largest independent specialty pharma company Specialised Therapeutics (ST) has joined global pharma consortium committed to collaborating to ...